Biopharma 3PL market seen topping $221 billion by 2030

The biopharmaceutical third-party logistics market reached $150.5 billion in 2025 and is forecast to hit $221.15 billion by 2030, according to The Business Research Company. Growth is being driven by more biologics, vaccines and personalized medicines moving through outsourced, temperature-sensitive supply chains.

Why it matters: - Biopharma companies are leaning harder on third-party logistics to move products that are fragile, highly regulated and often time-sensitive. - The market’s projected growth points to stronger demand for cold chain capacity, tracking tools and specialized storage as drug portfolios become more complex. - The shift matters for manufacturers, logistics providers and patients because supply chain failures can delay treatments and raise compliance risks.

What happened: - The Business Research Company said the global biopharmaceutical third-party logistics market reached $150.5 billion in 2025. - The market is projected to rise to $161.71 billion in 2026, according to the report. - The report forecasts the market will reach $221.15 billion by 2030. - The company released its Biopharmaceutical Third-Party Logistics Global Market Report 2026. - The report also offers a free sample.

The details: - The market’s 2025-2026 growth path implies a 7.4% compound annual growth rate. - The forecast through 2030 implies an 8.1% CAGR. - Growth in the historical period was driven by more biologics and vaccines, wider outsourcing by pharma companies, expanding global biopharma supply chains, stricter drug-transport rules and limited in-house logistics capacity. - The forecast is being supported by rising demand for personalized medicines, more cell and gene therapy distribution, higher investment in intelligent logistics platforms, tighter end-to-end supply chain visibility and more cross-border biopharma trade. - Expected trends include advanced cold chain logistics, more temperature-controlled transportation, broader real-time shipment tracking, specialized biopharma warehousing and stricter regulatory-compliant operations. - Biopharmaceutical third-party logistics means outside providers handle logistics functions for pharmaceutical companies. - Firms use these services to reduce costs and fill gaps in in-house logistics capabilities. - The model is especially important for products that need specialized transport and storage conditions. - Outsourcing is especially relevant for complex cryogenic supply chains that require specialized equipment and expertise. - In February 2024, Bureau of Transportation Statistics data showed for-hire freight shipments rose 1.8% in December 2023 from a year earlier. - The Freight Transportation Services Index increased from 136.6 in December 2022 to 139.1 in December 2023. - The report covers Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 edition adds market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, plus updated graphics and tables.

Between the lines: - The biggest growth driver is not just pharma expansion. It is the logistics burden created by products that require tight temperature control, regulatory oversight and specialized handling. - North America led the market in 2025 because of its mature pharmaceutical base and logistics infrastructure. - Asia-Pacific is expected to be the fastest-growing region as manufacturing capacity and supply chain investment expand. - The freight data cited in the report reinforces the broader shift toward outsourced logistics services.

What’s next: - The market is likely to keep favoring providers that can prove cold chain reliability, compliance and real-time visibility. - Competition should intensify around temperature-controlled transport, specialized warehousing and cross-border logistics for advanced therapies. - The company is directing interested readers to contact Saumya Sahay for more information. - The company lists contact numbers for the Americas, Asia and Europe, plus marketing@tbrc.info for email inquiries. - The Business Research Company also directs readers to its website and social channels, including LinkedIn, LinkedIn, Facebook, and X.

The bottom line: - Biopharma logistics is becoming a bigger, more specialized market as drug makers outsource the handling of complex therapies that cannot tolerate supply chain mistakes.